Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial

BACKGROUND: In previous clinical trials, patients with active rheumatoid arthritis (RA) treated with upadacitinib (UPA) have improved patient-reported outcomes (PROs). This post hoc analysis of SELECT-CHOICE, a phase 3 clinical trial, evaluated the impact of UPA vs abatacept (ABA) with background co...

Descripción completa

Detalles Bibliográficos
Autores principales: Bergman, Martin, Tundia, Namita, Martin, Naomi, Suboticki, Jessica L., Patel, Jayeshkumar, Goldschmidt, Debbie, Song, Yan, Wright, Grace C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229430/
https://www.ncbi.nlm.nih.gov/pubmed/35751108
http://dx.doi.org/10.1186/s13075-022-02813-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229430/
https://www.ncbi.nlm.nih.gov/pubmed/35751108
http://dx.doi.org/10.1186/s13075-022-02813-x

Ejemplares similares